Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 4/20 | 0.38 |
| ▸ | CETP | P11597 | 4/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609392 | 0.76 | ACP3 (0.41) | ACP3CETP | |
| SCHEMBL7606875 | 0.74 | ACP3 (0.39) | ACP3CETP | |
| SCHEMBL7608436 | 0.74 | CETP (0.40) | ACP3CETPPLA2G2D | |
| SCHEMBL7928443 | 0.74 | ACP3 (0.39) | ACP3CETPKIF11 | |
| SCHEMBL7604385 | 0.73 | ACP3 (0.41) | ACP3CETP | |
| SCHEMBL11650577 | 0.73 | CNR2 (0.41) | KIF11PPARGPPARA | |
| SCHEMBL7609376 | 0.72 | ACP3 (0.43) | ACP3PPARGPPARAMMP8 | |
| SCHEMBL7606180 | 0.70 | ACP3 (0.41) | ACP3PPARGPPARAMMP8 | |
| SCHEMBL7605240 | 0.70 | ACP3 (0.41) | ACP3CETPPLA2G2DPPARGPPARA | |
| SCHEMBL7925674 | 0.69 | KDM4E (0.38) | ACP3CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994707-A4 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-14 | — | — | EP | claimed |
| EP-0994707-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1998053812-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-0994707-A4 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARM INC (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-0994707-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6025345-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1998053812-A1 | INHIBITORS OF NAALADASE ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | ACP3 36/4885CETP 1402/4885KIF11 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.